Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Lapatinib|BIOLOGICAL: Trastuzumab|DRUG: Aromatase Inhibitors (AIs)
Sponsor: Novartis Pharmaceuticals